↓ Skip to main content
Embed badge What is this page?

Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) – a study protocol

Overview of attention for article published in BMC Cancer, June 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
62 Mendeley

What is this page?

Summary Twitter Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) – a study protocol
Published in
BMC Cancer, June 2017
DOI 10.1186/s12885-017-3433-z
Pubmed ID
28645260
Authors

Dennis Schrijnders, Geertruida H. de Bock, Sebastiaan T. Houweling, Kornelis J. J. van Hateren, Klaas H. Groenier, Jeffrey A. Johnson, Henk J. G. Bilo, Nanne Kleefstra, Gijs W. D. Landman

Abstract

Patients with type 2 diabetes (T2D) are at increased risk for developing cancer. As approximately 8% of the world's population is living with T2D, even a slight increase in cancer risk could result in an enormous impact on the number of persons developing cancer. In addition, several glucose lowering drug classes for treating patients with T2D have been associated with a difference in risk of cancer overall, and especially for obesity related cancers. In what way and to what degree cancer risk is modified by the use of different sulfonylureas (SU) is unclear. The primary aim of this study will be to evaluate within-class SU differences in obesity related cancer risk. Secondary aims will be to investigate within-class SU differences in risk for all cancers combined and site-specific cancers separately (i.e. breast, colorectal, prostate, bladder and lung cancer) and to account for duration-response relationships between individual SU use and cancer risk. Patients will be selected from a Dutch primary care cohort of patients with T2D linked with the Dutch Cancer Registration (ZODIAC-NCR). Within this cohort study annually collected clinical data (e.g. blood pressure, weight, HbA1c) and nationwide data on cancer incidence are available. Time-dependent cox proportional hazard analyses will be performed to evaluate SU cancer risk, adjusted for potential confounders. This study will be the first prospective cohort study investigating within-class SU differences in cancer risk and could contribute to improved decision making regarding the individual drugs within the class of SUs, and possibly improve quality of life and result in an increased cost-effectiveness of healthcare in patients with T2D. Nederlands Trialregister ( NTR6166 ), 6 Jan 2017.

View on publisher site

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 62 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 16%
Researcher 8 13%
Student > Ph. D. Student 7 11%
Lecturer 4 6%
Other 3 5%
Other 9 15%
Unknown 21 34%
Readers by discipline Count As %
Medicine and Dentistry 19 31%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Nursing and Health Professions 2 3%
Psychology 2 3%
Agricultural and Biological Sciences 2 3%
Other 7 11%
Unknown 28 45%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 August 2017.
All research outputs
#14,942,299
of 22,982,639 outputs
Outputs from BMC Cancer
#3,712
of 8,351 outputs
Outputs of similar age
#188,186
of 316,289 outputs
Outputs of similar age from BMC Cancer
#56
of 127 outputs
Altmetric has tracked 22,982,639 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,351 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,289 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 127 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.

This page is provided by Altmetric.